Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients.
+ 1 more risk
Weak fundamentals or lack of information.
Share Price & News
How has Arch Biopartners's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACHF.F has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: ACHF.F underperformed the US Life Sciences industry which returned 35.9% over the past year.
Return vs Market: ACHF.F underperformed the US Market which returned 16.3% over the past year.
Price Volatility Vs. Market
How volatile is Arch Biopartners's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Arch Biopartners undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Arch Biopartners is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Arch Biopartners has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of ACHF.F's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Arch Biopartners regulatory filings here.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Arch Biopartners forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arch Biopartners has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of ACHF.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Arch Biopartners's filings and announcementshere.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Arch Biopartners performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACHF.F is currently unprofitable.
Growing Profit Margin: ACHF.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACHF.F is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.
Accelerating Growth: Unable to compare ACHF.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACHF.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.7%).
Return on Equity
High ROE: ACHF.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Arch Biopartners's financial position?
Financial Position Analysis
Short Term Liabilities: ACHF.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ACHF.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ACHF.F has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ACHF.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACHF.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ACHF.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.5% each year
What is Arch Biopartners's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACHF.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACHF.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACHF.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACHF.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACHF.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Richard Muruve (49 yo)
Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and serves as its President May 12, 2010. Mr. Muruve served as Acting Chief Fi ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD74.77K) is below average for companies of similar size in the US market ($USD594.10K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
|Co-Founder||no data||no data||no data|
|Acting CFO & Director||10.33yrs||no data||0.63% |
|Independent Director||6.33yrs||no data||0.18% |
|Director||10.25yrs||no data||3.62% |
|Independent Director||6yrs||no data||0.13% |
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: ACHF.F's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ACHF.F insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.
Arch Biopartners Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Arch Biopartners Inc.
- Ticker: ACHF.F
- Exchange: OTCPK
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$59.818m
- Shares outstanding: 60.78m
- Website: https://www.archbiopartners.com
- Arch Biopartners Inc.
- 545 King Street West
- M5V 1M1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ACHF.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||May 2010|
|ARCH||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||May 2010|
Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant bacterial ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/08 23:45|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.